Asit Biotech

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2021, Asit Biotech has already paid €0.0107 in dividends. The last payout was in March 2021.

Financials

In the last quarter, Asit Biotech had revenue of €23.32M and net profit of €1.08M

(EUR)	June 2026	YoY
Revenue	23.32M	-
Gross profit	9.23M	-
Net profit	1.08M	-
EBITDA	1.85M	-

Fundamentals

Metric	Value
Market capitalization	€78.71K
Number of shares	4.23M
52-week high/low	€0.031 - €0.0145
Dividends	No
Beta	0.50
P/E ratio	7.83
PEG ratio	0.11
P/B ratio	1.16
P/S ratio	0.32

Company profile

ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.